Skip to main content
CND In the News

CND Life Sciences Mentioned in CNN Story About Robin Williams

By July 11, 2022August 29th, 2023No Comments

CND Life Sciences Mentioned in CNN Story About Robin Williams

“It wasn’t until Robin’s autopsy that we got an accurate diagnosis,” explains Susan Schneider Williams, widow of the late comedian, in a talk she gave at Life Itself—a health and wellness conference presented in partnership with CNN. Robin Williams was diagnosed with Parkinson’s disease a few months before his death, at which time his family learned he instead had dementia with Lewy bodies.

At first Schneider Williams said she didn’t think an accurate diagnosis would have made a difference given that there is no cure for Lewy body dementia (LBD). But now she says, “Diagnosis is everything.” A diagnosis would have allowed Williams to potentially participate in clinical trials, seek specialized care, join the LBD community, or donate to research efforts. “The bottom line is, Robin wouldn’t have had to feel so afraid, and we wouldn’t have had to waste so much precious time trying to figure out what was going on.”

Dr. James Galvin, a professor of neurology and director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine highlights two developments in diagnostic testing for LBD—a spinal fluid test from Amprion and the Syn-One Test® from CND Life Sciences. He notes that to be able to diagnose LBD in a living person is a huge advantage for the patient and helps to advance research.

Read the story on CNN

CND Life Sciences

CND Life Sciences is the creator of the Syn-One Test™, the world’s first commercially available test to visualize abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test is an objective, evidence-based diagnostic tool to aid in the diagnosis of Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, or REM sleep behavior disorder.